Horama is developing gene therapies for rare retinal diseases. Its lead program is the most advanced gene therapy for the treatment PDE6β-related retinitis pigmentosa. biopharmaceuticalsPrivateVisit Website http://www.horama.fr/ Additional Portfolio Companies Abcuro Adicet Bio AgomAb Therapeutics Allena Pharmaceuticals ArQule Cathworks cCAM Biotherapeutics CheckCap CytoReason Dynacure Eloxx Pharmaceuticals Enlivex Therapeutics Eyevensys EyeYon ForSight Vision6 (“V6”) Genocea Horama IMEL Biotherapeutics Immunic Therapeutics Kamari Pharma Keros Therapeutics Kite Pharma Levation Pharma LogicBio Therapeutics Lutris Pharma Mereo BioPharma Metabomed NovellusDX Ocon Medical Opiant PACT Pharma Pi Therapeutics Prevail Therapeutics Precirix (Formerly Camel-IDS) ProQR Protalix Raziel Therapeutics ReWalk Saniona SilverBack Therapeutics Soligenix Stargazer Pharmaceuticals VBI Vaccines Step Pharma StimatixGI Sweetch TargEDys Vascular Graft Solutions UroGen V-Wave November 15, 2017 Previous Project Next Project